Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 7Phase 3 2Phase 4 1Phase 1/2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Breast Neoplasms 10Carcinoma, Non-Small-Cell Lung 6Prostatic Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myeloid, Acute 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Ovarian Neoplasms 3Lung Neoplasms 3Thrombosis 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Recurrence 2Neoplasms 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Multiple Myeloma 2Disease 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Thrombophilia 1Thrombocytopenia 1Thoracic Neoplasms 1Skin Neoplasms 1Pituitary Neoplasms 1Pediatric Solid Tumor, Unspecified, Protocol Specific 1Papillomavirus Infections 1

Interventions

Dexamethasone 168Bortezomib 90Lenalidomide 85Thalidomide 44daratumumab 43pomalidomide 42Melphalan 39Cyclophosphamide 33carfilzomib 29Calcium Dobesilate 27Prednisone 19Doxorubicin 16elotuzumab 14Filgrastim 12ixazomib 11isatuximab 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10belantamab mafodotin 9Granulocyte Colony-Stimulating Factor 9Zoledronic Acid 8selinexor 7dexamethasone acetate 7Epoetin Alfa 7Etoposide 6fludarabine 5Cisplatin 5Carmustine 5Radiotherapy 4Mycophenolic Acid 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Multiple Myeloma × Injections × Clear all
NCT05020236 2026-05-05

MAGNETISMM-5

Pfizer

Phase 3 Recruiting
944 enrolled
Plasma cell

Multiple Myeloma

NCT04288765 2021-07-09

Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma

Grupo Cooperativo de Hemopatías Malignas

Phase 3 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡